Cryptococcus neoformans: Historical curiosity to modern pathogen

Yeast

Volumn 31, Issue 2, 2014, Pages 47-60

  Srikanta, Deepa ^a   Santiago Tirado, Felipe H ^a   Doering, Tamara L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Capsule; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Meningitis; Pathogenic fungus; Yeast

Indexed keywords

CAPSULE; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; MENINGITIS; PATHOGENIC FUNGUS; YEAST;

ANIMALS; BACTERIAL PROTEINS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MICROBIOLOGY;

EID: 84895076256     PISSN: 0749503X     EISSN: 10970061     Source Type: Journal    
DOI: 10.1002/yea.2997     Document Type: Article

References (190)

1. Alvarez M, Burn T, Luo Y, et al. 2009. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol 9: 51.
2. Alvarez M, Casadevall A. 2006. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol 16: 2161-2165.
3. Alvarez M, Casadevall A. 2007. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol 8: 16.
4. Apidianakis Y, Rahme LG, Heitman J, et al. 2004. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryot Cell 3: 413-419.
5. Artavanis-Tsakonas K, Love JC, Ploegh HL, Vyas JM. 2006. Recruitment of CD63 to Cryptococcus neoformans phagosomes requires acidification. Proc Natl Acad Sci U S A 103: 15945-15950.
6. Baker LG, Lodge JK. 2012a. Galactose-inducible promoters in Cryptococcus neoformans var. grubii. Methods Mol Biol 845: 211-226.
7. Baker LG, Lodge JK. 2012b. Multiple gene deletion in Cryptococcus neoformans using the Cre-lox system. Methods Mol Biol 845: 85-98.
8. Baker LG, Specht CA, Donlin MJ, Lodge JK. 2007. Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryot Cell 6: 855-867.
9. Barbosa FM, Fonseca FL, Holandino C, et al. 2006. Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage. Microbes Infect 8: 493-502.
10. Barnett JA. 2010. A history of research on yeasts 14: medical yeasts part 2, Cryptococcus neoformans. Yeast 27: 875-904.
11. Belay T, Cherniak R, Kozel TR, Casadevall A. 1997. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun 65: 718-728.
12. Bose I, Doering TL. 2011. Efficient implementation of RNA interference in the pathogenic yeast Cryptococcus neoformans. J Microbiol Methods 86: 156-159.
13. Botts MR, Giles SS, Gates MA, et al. 2009. Isolation and characterization of Cryptococcus neoformans spores reveal a critical role for capsule biosynthesis genes in spore biogenesis. Eukaryot Cell 8: 595-605.
14. Botts MR, Hull CM. 2010. Dueling in the lung: how Cryptococcus spores race the host for survival. Curr Opin Microbiol 13: 437-442.
15. Brown JC, Madhani HD. 2012. Approaching the functional annotation of fungal virulence factors using cross-species genetic interaction profiling. PLoS Genet 8: e1003168.
16. Brown SM, Campbell LT, Lodge JK. 2007. Cryptococcus neoformans, a fungus under stress. Curr Opin Microbiol 10: 320-325.
17. Busse O. 1894. Uber parasitare Zelleinschlusse und ihre Zuchtung. Centralbl Bakt Parasit 16.
18. Byrnes EJ III, Bildfell RJ, Frank SA, et al. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis 199: 1081-1086.
19. Casadevall A, DeShaw M, Fan M, et al. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun 62: 3864-3872.
20. Casadevall A, Pirofski L. 2001. Host-pathogen interactions: the attributes of virulence. J Infect Dis 184: 337-344.
21. Chang YC, Kwon-Chung KJ. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14: 4912-4919.
22. Charlier C, Chretien F, Baudrimont M, et al. 2005. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 166: 421-432.
23. Chen J, Varma A, Diaz MR, et al. 2008. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14: 755-762.
24. Chen SC, Wright LC, Santangelo RT, et al. 1997. Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Infect Immun 65: 405-411.
25. Chen SH, Stins MF, Huang SH, et al. 2003. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 52: 961-970.
26. Chun CD, Brown JC, Madhani HD. 2011. A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans. Cell Host Microbe 9: 243-251.
27. Clemens KS, Stevens DA. 2011. Cryptococcosis in experimental animals: lessons learned. In Cryptococcus: From Human Pathogen to Model Yeast, Heitman J, Kozel T, Kwon-Chung KJ, et al. (eds). ASM Press: Washington, DC; 473-488.
28. Cox GM, Toffaletti DL, Perfect JR. 1996. Dominant selection system for use in Cryptococcus neoformans. J Med Vet Mycol 34: 385-391.
29. Cramer KL, Gerrald QD, Nichols CB, et al. 2006. Transcription factor Nrg1 mediates capsule formation, stress response, and pathogenesis in Cryptococcus neoformans. Eukaryot Cell 5: 1147-1156.
30. D'Souza CA, Kronstad JW, Taylor G, et al. 2011. Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio 2: 1-11.
31. Davidson RC, Blankenship JR, Kraus PR, et al. 2002. A PCR-based strategy to generate integrative targeting alleles with large regions of homology. Microbiology 148: 2607-2615.
32. De Jesus M, Nicola AM, Rodrigues ML, et al. 2009. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan. Eukaryot Cell 8: 96-103.
33. del Poeta M. 2004. Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot Cell 3: 1067-1075.
34. del Poeta M, Toffaletti DL, Rude TH, et al. 1999. Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect Immun 67: 1812-1820.
35. Diamond RD, Bennett JE. 1973. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun 7: 231-236.
36. Ding C, Festa RA, Chen YL, et al. 2013. Cryptococcus neoformans copper detoxification machinery is critical for fungal virulence. Cell Host Microbe 13: 265-276.
37. Dixit A, Carroll SF, Qureshi ST. 2009. Cryptococcus gattii: an emerging cause of fungal disease in North America. Interdiscip Perspect Infect Dis 2009: 840452.
38. Doering TL. 2009. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol 63: 223-247.
39. Dumesic PA, Natarajan P, Chen C, et al. 2013. Stalled spliceosomes are a signal for RNAi-mediated genome defense. Cell 152: 957-968.
40. Edman JC. 1992. Isolation of telomerelike sequences from Cryptococcus neoformans and their use in high-efficiency transformation. Mol Cell Biol 12: 2777-2783.
41. Edman JC, Kwon-Chung KJ. 1990. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol Cell Biol 10: 4538-4544.
42. Eisenman HC, Casadevall A, McClelland EE. 2007. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep 9: 457-464.
43. Ellis DH, Pfeiffer TJ. 1990. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 28: 1642-1644.
44. Evans EE. 1950. The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of the capsular and agglutination reactions. J Immunol 64: 423-430.
45. Feldmesser M, Rivera J, Kress Y, et al. 2000. Antibody interactions with the capsule of Cryptococcus neoformans. Infect Immun 68: 3642-3650.
46. Feldmesser M, Tucker S, Casadevall A. 2001. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 9: 273-278.
47. Florio AR, Ferrari S, De Carolis E, et al. 2011. Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A. BMC Microbiol 11: 97.
48. Fonseca FL, Guimaraes AJ, Kmetzsch L, et al. 2013. Binding of the wheat germ lectin to Cryptococcus neoformans chito-oligomers affects multiple mechanisms required for fungal pathogenesis. Fung Genet Biol 60: 64-73.
49. Forche A, Xu J, Vilgalys R, Mitchell TG. 2000. Development and characterization of a genetic linkage map of Cryptococcus neoformans var. neoformans using amplified fragment length polymorphisms and other markers. Fung Genet Biol 31: 189-203.
50. Fox DS, Cox GM, Heitman J. 2003. Phospholipid-binding protein Cts1 controls septation and functions coordinately with calcineurin in Cryptococcus neoformans. Eukaryot Cell 2: 1025-1035.
51. Franzot SP, Salkin IF, Casadevall A. 1999. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 37: 838-840.
52. Fraser JA, Huang JC, Pukkila-Worley R, et al. 2005. Chromosomal translocation and segmental duplication in Cryptococcus neoformans. Eukaryot Cell 4: 401-406.
53. Fries BC, Chen F, Currie BP, Casadevall A. 1996. Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol 34: 1531-1534.
54. Fu J, Hettler E, Wickes BL. 2006. Split marker transformation increases homologous integration frequency in Cryptococcus neoformans. Fung Genet Biol 43: 200-212.
55. Fyfe M, MacDougall L, Romney M, et al. 2008. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can Commun Dis Rep 34: 1-12.
56. Gates-Hollingsworth MA, Kozel TR. 2009. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol 74: 126-138.
57. Gates MA, Thorkildson P, Kozel TR. 2004. Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol 52: 13-24.
58. Giles SS, Dagenais TR, Botts MR, et al. 2009. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun 77: 3491-3500.
59. Goebels C, Thonn A, Gonzalez-Hilarion S, et al. 2013. Introns regulate gene expression in Cryptococcus neoformans in a Pab2p dependent pathway. PLoS Genet 9: e1003686.
60. Goins CL, Gerik KJ, Lodge JK. 2006. Improvements to gene deletion in the fungal pathogen Cryptococcus neoformans: absence of Ku proteins increases homologous recombination, and co-transformation of independent DNA molecules allows rapid complementation of deletion phenotypes. Fung Genet Biol 43: 531-544.
61. Goldman DL, Casadevall A, Cho Y, Lee SC. 1996. Cryptococcus neoformans meningitis in the rat. Lab Invest 75: 759-770.
62. Goulart L, Rosa e Silva LK, Chiapello L, et al. 2010. Cryptococcus neoformans and Cryptococcus gattii genes preferentially expressed during rat macrophage infection. Med Mycol 48: 932-941.
63. Haynes BC, Skowyra ML, Spencer SJ, et al. 2011. Toward an integrated model of capsule regulation in Cryptococcus neoformans. PLoS Pathog 7: e1002411.
64. He X, Lyons DM, Toffaletti DL, et al. 2012. Virulence factors identified by Cryptococcus neoformans mutant screen differentially modulate lung immune responses and brain dissemination. Am J Pathol 181: 1356-1366.
65. Heiss C, Skowyra ML, Liu H, et al. 2013. Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. J Biol Chem 288: 10994-11003.
66. Heitman J, Allen B, Alspaugh JA, et al. 1999a. On the origins of congenic MATα and MATa strains of the pathogenic yeast Cryptococcus neoformans. Fung Genet Biol 28: 1-5.
67. Heitman J, Casadevall A, Lodge JK, Perfect JR. 1999b. The Cryptococcus neoformans genome sequencing project. Mycopathologia 148: 1-7.
68. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A. 2011. Cryptococcus From Human Pathogen to Model Yeast. ASM Press: Washington DC.
69. Hu G, Cheng PY, Sham A, et al. 2008. Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol Microbiol 69: 1456-1475.
70. Hua J, Meyer JD, Lodge JK. 2000. Development of positive selectable markers for the fungal pathogen Cryptococcus neoformans. Clin Diagn Lab Immunol 7: 125-128.
71. Hull CM, Heitman J. 2002. Genetics of Cryptococcus neoformans. Annu Rev Genet 36: 557-615.
72. Idnurm A, Reedy JL, Nussbaum JC, Heitman J. 2004. Cryptococcus neoformans virulence gene discovery through insertional mutagenesis. Eukaryot Cell 3: 420-429.
73. Idnurm A, Walton FJ, Floyd A, et al. 2009. Identification of ENA1 as a virulence gene of the human pathogenic fungus Cryptococcus neoformans through signature-tagged insertional mutagenesis. Eukaryot Cell 8: 315-326.
74. Igreja RP, Lazera Mdos S, Wanke B, et al. 2004. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro. Med Mycol 42: 229-238.
75. Jacobson ES, Jenkins ND, Todd JM. 1994. Relationship between superoxide dismutase and melanin in a pathogenic fungus. Infect Immun 62: 4085-4086.
76. Janbon G, Doering TL. 2011. Biosynthesis and genetics of the cryptococcal capsule. In Cryptococcus: From Human Pathogen to Model Yeast, Heitman J, Kozel T, Kwon-Chung J, Perfect J, et al. (eds). ASM Press: Washington, DC; 27-42.
77. Janbon G, Maeng S, Yang DH, et al. 2010. Characterizing the role of RNA silencing components in Cryptococcus neoformans. Fungal Genet Biol 47: 1070-1080.
78. Johnston SA, May RC. 2013. Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen. Cell Microbiol 15: 403-411.
79. Jong A, Wu CH, Gonzales-Gomez I, et al. 2012. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem 287: 15298-15306.
80. Jong A, Wu CH, Prasadarao NV, et al. 2008a. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-α activation. Cell Microbiol 10: 1854-1865.
81. Jong A, Wu CH, Shackleford GM, et al. 2008b. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol 10: 1313-1326.
82. Kent CR, Ortiz-Bermudez P, Giles SS, Hull CM. 2008. Formulation of a defined V8 medium for induction of sexual development of Cryptococcus neoformans. Appl Environm Microbiol 74: 6248-6253.
83. Kidd SE, Hagen F, Tscharke RL, et al. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101: 17258-17263.
84. Kim KS. 2008. Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol 6: 625-634.
85. Kim MS, Kim SY, Jung KW, Bahn YS. 2012. Targeted gene disruption in Cryptococcus neoformans using double-joint PCR with split dominant selectable markers. Methods Mol Biol 845: 67-84.
86. 2 sensing pathway via differential expression of carbonic anhydrase in Cryptococcus neoformans. Genetics 185: 1207-1219.
87. Kirkpatrick WR, Najvar LK, Bocanegra R, et al. 2007. New guinea pig model of cryptococcal meningitis. Antimicrob Agents Chemother 51: 3011-3013.
88. Kozel TR, Follette JL. 1981. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun 31: 978-984.
89. Kozubowski L, Heitman J. 2012. Profiling a killer, the development of Cryptococcus neoformans. FEMS Microbiol Rev 36: 78-94.
90. Kumar P, Yang M, Haynes BC, et al. 2011. Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol 21: 597-602.
91. Kupfer DM, Drabenstot SD, Buchanan KL, et al. 2004. Introns and splicing elements of five diverse fungi. Eukaryot Cell 3: 1088-1100.
92. Kwon-Chung KJ. 1975. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 67: 1197-1200.
93. Kwon-Chung KJ. 1976. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia 68: 943-946.
94. Kwon-Chung KJ, Varma A. 2006. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 6: 574-587.
95. Kwon-Chung KJ, Varma A, Edman JC, Bennett JE. 1992. Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J Med Vet Mycol 30: 61-69.
96. Lengeler KB, Fox DS, Fraser JA, et al. 2002. Mating-type locus of Cryptococcus neoformans: a step in the evolution of sex chromosomes. Eukaryot Cell 1: 704-718.
97. Levitz SM, Nong SH, Seetoo KF, et al. 1999. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 67: 885-890.
98. Li Z, Pan J, Zhu X. 2012. [Agrobacterium tumefaciens-mediated transformation (ATMT) for the screening for genes involved in laccase glucose repression in the pathogenic yeast Cryptococcus neoformans]. Acta Microbiol Sin 52: 44-51.
99. Lian T, Simmer MI, D'Souza CA, et al. 2005. Iron-regulated transcription and capsule formation in the fungal pathogen Cryptococcus neoformans. Mol Microbiol 55: 1452-1472.
100. Lin X, Hull CM, Heitman J. 2005. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434: 1017-1021.
101. Littman ML, Zimmerman LE. 1956. Cryptococcosis. Grune & Stratton: New York; 121-146.
102. Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG. 2006. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172: 2223-2238.
103. Liu H, Cottrell TR, Pierini LM, et al. 2002. RNA interference in the pathogenic fungus Cryptococcus neoformans. Genetics 160: 463-470.
104. Liu OW, Chun CD, Chow ED, et al. 2008. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135: 174-188.
105. Liu X, Hu G, Panepinto J, Williamson PR. 2006. Role of a VPS41 homologue in starvation response, intracellular survival and virulence of Cryptococcus neoformans. Mol Microbiol 61: 1132-1146.
106. Loftus BJ, Fung E, Roncaglia P, et al. 2005. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307: 1321-1324.
107. Ma H, Croudace JE, Lammas DA, May RC. 2006. Expulsion of live pathogenic yeast by macrophages. Curr Biol 16: 2156-2160.
108. Ma H, Croudace JE, Lammas DA, May RC. 2007. Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol 8: 15.
109. Ma H, Hagen F, Stekel DJ, Johnston SA, et al. 2009. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci U S A 106: 12980-12985.
110. MacDougall L, Kidd SE, Galanis E, et al. 2007. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 42-50.
111. Madhani HD. 2012. Cryptococcus neoformans Gene Knockout Resource, NIH: Project No. 5R01AI100272.
112. Malliaris SD, Steenbergen JN, Casadevall A. 2004. Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth. Med Mycol 42: 149-158.
113. Mansour MK, Levitz SM. 2002. Interactions of fungi with phagocytes. Curr Opin Microbiol 5: 359-365.
114. McClelland CM, Chang YC, Kwon-Chung KJ. 2005. High frequency transformation of Cryptococcus neoformans and Cryptococcus gattii by Agrobacterium tumefaciens. Fung Genet Biol 42: 904-913.
115. McClelland CM, Chang YC, Varma A, Kwon-Chung KJ. 2004. Uniqueness of the mating system in Cryptococcus neoformans. Trends Microbiol 12: 208-212.
116. McDade HC, Cox GM. 2001. A new dominant selectable marker for use in Cryptococcus neoformans. Med Mycol 39: 151-154.
117. Meyer W, Aanensen DM, Boekhout T, et al. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47: 561-570.
118. Missall TA, Pusateri ME, Lodge JK. 2004. Thiol peroxidase is critical for virulence and resistance to nitric oxide and peroxide in the fungal pathogen, Cryptococcus neoformans. Mol Microbiol 51: 1447-1458.
119. Mitchell TG, Perfect JR. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8: 515-548.
120. Moyrand F, Klaproth B, Himmelreich U, et al. 2002. Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol 45: 837-849.
121. Mukherjee J, Scharff MD, Casadevall A. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 60: 4534-4541.
122. Mylonakis E. 2008. Galleria mellonella and the study of fungal pathogenesis: making the case for another genetically tractable model host. Mycopathologia 165: 1-3.
123. Mylonakis E, Ausubel FM, Perfect JR, et al. 2002. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A 99: 15675-15680.
124. Mylonakis E, Ausubel FM, Tang RJ, Calderwood SB. 2003. The art of serendipity: killing of Caenorhabditis elegans by human pathogens as a model of bacterial and fungal pathogenesis. Expert Rev Anti Infect Ther 1: 167-173.
125. Mylonakis E, Moreno R, El Khoury JB, et al. 2005. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 73: 3842-3850.
126. Neilson JB, Ivey MH, Bulmer GS. 1978. Cryptococcus neoformans: pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect Immun 20: 262-266.
127. Nielsen K, Cox GM, Wang P, et al. 2003. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and α isolates. Infect Immun 71: 4831-4841.
128. Nelson RT, Pryor BA, Lodge JK. 2003. Sequence length required for homologous recombination in Cryptococcus neoformans. Fung Genet Biol 38: 1-9.
129. Nosanchuk JD, Casadevall A. 2006. Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 50: 3519-3528.
130. O'Meara TR, Alspaugh JA. 2012. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev 25: 387-408.
131. O'Meara TR, Holmer SM, Selvig K, et al. 2013. Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. MBio 4: 1-13.
132. O'Meara TR, Norton D, Price MS, et al. 2010. Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule. PLoS Pathog 6: e1000776.
133. Okagaki LH, Nielsen K. 2012. Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot Cell 11: 820-826.
134. Okagaki LH, Strain AK, Nielsen JN, et al. 2010. Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog 6: e1000953.
135. Ory JJ, Griffith CL, Doering TL. 2004. An efficiently regulated promoter system for Cryptococcus neoformans utilizing the CTR4 promoter. Yeast 21: 919-926.
136. Park BJ, Wannemuehler KA, Marston BJ, et al. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
137. Park YD, Williamson PR. 2012. 'Popping the clutch': novel mechanisms regulating sexual development in Cryptococcus neoformans. Mycopathologia 173: 359-366.
138. Patel RD, Lodge JK, Baker LG. 2010. Going green in Cryptococcus neoformans: the recycling of a selectable drug marker. Fung Genet Biol 47: 191-198.
139. Perfect JR. 2005. Cryptococcus neoformans: a sugar-coated killer with designer genes. FEMS Immunol Med Microbiol 45: 395-404.
140. Perfect JR, Dismukes WE, Dromer F, et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50: 291-322.
141. Perfect JR, Lang SD, Durack DT. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101: 177-194.
142. Polacheck I, Lebens GA. 1989. Electrophoretic karyotype of the pathogenic yeast Cryptococcus neoformans. J Gen Microbiol 135: 65-71.
143. Pukkila-Worley R, Gerrald QD, Kraus PR, et al. 2005. Transcriptional network of multiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryot Cell 4: 190-201.
144. Qin QM, Luo J, Lin X, et al. 2011. Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. PLoS Pathog 7: e1002078.
145. Ralph P, Prichard J, Cohn M. 1975. Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. J Immunol 114: 898-905.
146. Reese AJ, Doering TL. 2003. Cell wall α-1, 3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50: 1401-1409.
147. Reilly MC, Aoki K, Wang ZA, et al. 2011. A xylosylphosphotransferase of Cryptococcus neoformans acts in protein O-glycan synthesis. J Biol Chem 286: 26888-26899.
148. Sabiiti W, May RC, Pursall ER. 2012. Experimental models of cryptococcosis. Int J Microbiol 2012: 626745.
149. Sanfelice F. 1894. Contributo alla morfologia e biologia dei blastomiceti che si sviluppano nei succhi de alcuni frutti. Ann Ist Ig R Univ Roma 4: 463-469.
150. Schein JE, Tangen KL, Chiu R, et al. 2002. Physical maps for genome analysis of serotype A and D strains of the fungal pathogen Cryptococcus neoformans. Genome Res 12: 1445-1453.
151. Shadomy HJ, Utz JP. 1966. Preliminary studies on a hypha-forming mutant of Cryptococcus neoformans. Mycologia 58: 383-390.
152. Sharpton TJ, Neafsey DE, Galagan JE, Taylor JW. 2008. Mechanisms of intron gain and loss in Cryptococcus. Genome Biol 9: R24.
153. Skowyra ML, Doering TL. 2012. RNA interference in Cryptococcus neoformans. Methods Mol Biol 845: 165-186.
154. Sorrell TC, Brownlee AG, Ruma P, et al. 1996. Natural environmental sources of Cryptococcus neoformans var. gattii. J Clin Microbiol 34: 1261-1263.
155. Springer DJ, Ren P, Raina R, et al. 2010. Extracellular fibrils of pathogenic yeast Cryptococcus gattii are important for ecological niche, murine virulence and human neutrophil interactions. PLoS One 5: e10978.
156. Srikanta D, Yang M, Williams M, Doering TL. 2011. A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infection. PLoS One 6: e22773.
157. Steen BR, Lian T, Zuyderduyn S, et al. 2002. Temperature-regulated transcription in the pathogenic fungus Cryptococcus neoformans. Genome Res 12: 1386-1400.
158. Steen BR, Zuyderduyn S, Toffaletti DL, et al. 2003. Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell 2: 1336-1349.
159. Steenbergen JN, Casadevall A. 2003. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect 5: 667-675.
160. Steenbergen JN, Nosanchuk JD, Malliaris SD, Casadevall A. 2003. Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun 71: 4862-4872.
161. Steenbergen JN, Shuman HA, Casadevall A. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A 98: 15245-15250.
162. Stie J, Fox D. 2012. Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology 158: 240-258.
163. Toffaletti DL, Rude TH, Johnston SA, et al. 1993. Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol 175: 1405-1411.
164. Tommasino N, Villani M, Qureshi A, et al. 2008. Atf2 transcription factor binds to the APP1 promoter in Cryptococcus neoformans: stimulatory effect of diacylglycerol. Eukaryot Cell 7: 294-301.
165. Tseng HK, Liu CP, Price MS, et al. 2012. Identification of genes from the fungal pathogen Cryptococcus neoformans related to transmigration into the central nervous system. PLoS One 7: e45083.
166. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26: 171-176.
167. Upadhya R, Campbell LT, Donlin MJ, et al. 2013. Global transcriptome profile of Cryptococcus neoformans during exposure to hydrogen peroxide induced oxidative stress. PLoS One 8: e55110.
168. Vallim MA, Nichols CB, Fernandes L, et al. 2005. A Rac homolog functions downstream of Ras1 to control hyphal differentiation and high-temperature growth in the pathogenic fungus Cryptococcus neoformans. Eukaryot Cell 4: 1066-1078.
169. Varma A, Edman JC, Kwon-Chung KJ. 1992. Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect Immun 60: 1101-1108.
170. Varma A, Kwon-Chung KJ. 1998. Construction of stable episomes in Cryptococcus neoformans. Curr Genet 34: 60-66.
171. Varma A, Kwon-Chung KJ. 1999. Characterization of the glyceraldehyde-3-phosphate dehydrogenase gene and the use of its promoter for heterologous expression in Cryptococcus neoformans, a human pathogen. Gene 232: 155-163.
172. Varma A, Wu S, Guo N, et al. 2006. Identification of a novel gene, URE2, that functionally complements a urease-negative clinical strain of Cryptococcus neoformans. Microbiology 152: 3723-3731.
173. Vecchiarelli A, Pericolini E, Gabrielli E, et al. 2013. Elucidating the immunological function of the Cryptococcus neoformans capsule. Future Microbiol 8: 1107-1116.
174. Velagapudi R, Hsueh YP, Geunes-Boyer S, et al. 2009. Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 77: 4345-4355.
175. Vu K, Weksler B, Romero I, et al. 2009. Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot Cell 8: 1803-1807.
176. Wang L, Zhai B, Lin X. 2012. The link between morphotype transition and virulence in Cryptococcus neoformans. PLoS Pathog 8: e1002765.
177. Wang X, Hsueh YP, Li W, et al. 2010. Sex-induced silencing defends the genome of Cryptococcus neoformans via RNAi. Genes Dev 24: 2566-2582.
178. Warpeha KM, Park YD, Williamson PR. 2013. Susceptibility of intact germinating Arabidopsis thaliana to human fungal pathogens Cryptococcus neoformans and C. gattii. Appl Environm Microbiol 79: 2979-2988.
179. Waterman SR, Park YD, Raja M, et al. 2012. Role of CTR4 in the virulence of Cryptococcus neoformans. MBio 3: 1-11.
180. Wilson DE, Bennett JE, Bailey JW. 1968. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 127: 820-823.
181. Wong B, Perfect JR, Beggs S, Wright KA. 1990. Production of the hexitol d-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun 58: 1664-1670.
182. World Health Organization. 2002. Revised global burden of disease (GBD) 2002 estimates: http://www.who.int/healthinfo/bodgbd2002revised/en/index.html
183. Zaragoza O. 2011. Multiple disguises for the same party: the concepts of morphogenesis and phenotypic variations in Cryptococcus neoformans. Front Microbiol 2: 181.
184. Zaragoza O, Alvarez M, Telzak A, et al. 2007. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun 75: 2729-2739.
185. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, et al. 2010. Fungal cell gigantism during mammalian infection. PLoS Pathog 6: e1000945.
186. Zaragoza O, Nielsen K. 2013. Titan cells in Cryptococcus neoformans: cells with a giant impact. Curr Opin Microbiol 16(4): 409-13.
187. Zaragoza O, Rodrigues ML, De Jesus M, et al. 2009. The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 68: 133-216.
188. Zhai B, Zhu P, Foyle D, et al. 2013. Congenic strains of the filamentous form of Cryptococcus neoformans for studies of fungal morphogenesis and virulence. Infect Immun 81(7): 2626-37.
189. Zhang S, Varma A, Williamson PR. 1999. The yeast Cryptococcus neoformans uses 'mammalian' enhancer sites in the regulation of the virulence gene, CNLAC1. Gene 227: 231-240.
190. Zhu X, Williamson PR. 2004. Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res 5: 1-10.